News
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
2016
-
Dec 22, 2016
Avastin® Received Orphan Drug Designation
for the Treatment of Malignant Pleural Mesothelioma
[PDF 100KB] -
Dec 22, 2016
PharmaMar and Chugai Pharmaceutical Enter into
a License and Commercialization Agreement for PM1183 in Japan
[PDF 70KB] -
Dec 22, 2016
Chugai’s Bispecific Antibody “Emicizumab” for Hemophilia A
Meets Primary Endpoint in Phase lll Study
- emicizumab prophylaxis shown to reduce bleeding in patients with inhibitors - [PDF 87KB] -
Dec 19, 2016
ACTEMRA® SC Injections Win a Prize of “WorldStar Award 2017” at the WPO’s WorldStar Packaging Awards
[PDF 101KB] -
Dec 16, 2016
Anti-Influenza Drug, Tamiflu® Filed for Additional Dosage and Administration for Newborns and Infants by Public Knowledge-Based Application
[PDF 67KB] -
Dec 09, 2016
Personnel Changes
[PDF 123KB] -
Nov 30, 2016
Filing for Approval of “Actemra®” for Additional Indication of
“Large Vessel Vasculitis,” the Designated Intractable Disease
[PDF 67KB] -
Nov 28, 2016
Chugai and Berlin-Chemie - the Menarini Group Announce
Global License Agreement for an Anti-cancer Agent, PA799
[PDF 72KB] -
Oct 20, 2016
F. Hoffmann-La Roche Announces Third Quarter Sales 2016
[PDF 82KB] -
Oct 05, 2016
Chugai’s ACTEMRA®/RoACTEMRA® Receives Breakthrough Therapy Designation from US FDA for Giant Cell Arteritis
[PDF 150KB] -
Oct 04, 2016
Chugai’s Alecensa® Receives Breakthrough Therapy Designation from FDA for First-Line Treatment of ALK Positive Non-Small Cell Lung Cancer
-- Alecensa’s Second Designation and the Fourth Designation Overall for Three Chugai Originated Drugs -- [PDF 132KB] -
Sep 28, 2016
Chugai and Maruho Announce License Agreement of Nemolizumab (CIM331),
a Novel Biologic in the Skin Disease Area for the Japanese Market
[PDF 98KB] -
Sep 16, 2016
Contribution of Para-transit Vehicles to Welfare Services
[PDF 193KB] -
Sep 14, 2016
Chugai Selected for the Third Consecutive Year
for Dow Jones Sustainability Asia Pacific Index
[PDF 127KB] -
Sep 01, 2016
Chugai Transfers the Manufacturing and Marketing Rights of VESANOID® to Fuji Pharma
[PDF 52KB] -
Aug 31, 2016
ACTEMRA® Subcutaneous Injection Wins a Prize at the JAPAN PACKAGING CONTEST 2016
- Appreciation for Patient-Oriented Design - [PDF 119KB] -
Aug 26, 2016
Chugai receives Orphan Drug Designation for Emicizumab
- Preventing and Reducing the Frequency of Bleeding Episodes in Congenital FVlll Deficiency Patients with Inhibitors - [PDF 150KB] -
Aug 26, 2016
Anti-Cancer Agent "Xeloda®,"
Obtained Approval for Additional Indication of "Adjuvant Chemotherapy for Rectal Cancer"
[PDF 166KB] -
Aug 25, 2016
Application for Approval of Additional Dosage for
"Actemra® Subcutaneous Injection" in Patients with Rheumatoid Arthritis Who Inadequately Respond to Every Other Week Dosage
[PDF 71KB] -
Jul 28, 2016
Chugai’s Emicizumab Showed Continued Benefits in Patients with Hemophilia A
－Update from Japanese P I/II study presented at WFH 2016－ [PDF 147KB] -
Jul 21, 2016
F. Hoffmann-La Roche Announces Half Year Results 2016
[PDF 104KB] -
Jul 21, 2016
Chugai and Galderma Announce Global License Agreement
for Nemolizumab (CIM331), Novel Biologic for Skin Diseases
[PDF 122KB] -
Jun 21, 2016
Chugai and Maruho Announce the Launch of
"Marduox® Ointment," for Psoriasis Vulgaris
(Combination Topical Ointment)
[PDF 76KB] -
Jun 01, 2016
Chugai Announces License Agreement for Recycling Antibody SA237
[PDF 71KB] -
May 26, 2016
Chugai’s Bispecific Antibody “ACE910/Emicizumab” Phase l Data in Patients with Hemophilia A
Published in The New England Journal Of Medicine Online
-- First NEJM Publication of Chugai’s Drug Candidate -- [PDF 129KB] -
May 23, 2016
Anti-Cancer Agent “Avastin®,” Obtained Approval for Additional Indication of Advanced or Recurrent Cervical Cancer
[PDF 203KB] -
May 19, 2016
Comprehensive Collaboration Agreement between Osaka University and Chugai
[PDF 141KB] -
May 19, 2016
Chugai to Present Japanese Phase III Results on Alecensa® at ASCO
[PDF 167KB] -
May 16, 2016
Efficacy of "Actemra® Subcutaneous Injection" Confirmed in
Dose Interval Reduction Study in Patients with Rheumatoid Arthritis Who Inadequately Respond to Bi-weekly Dose
[PDF 79KB] -
May 16, 2016
Donation to "Peking University Chugai Medical Foundation" Intended to Support Medical Students at Peking University
[PDF 70KB] -
May 13, 2016
Immunosuppressant “CellCept®”
Obtained Approval for Additional Indication of
“Lupus Nephritis”
[PDF 72KB] -
May 13, 2016
“Team Chugai” to Take Part in “Relay for Life Japan”
Using “3D Adventure Experience (Lung Cancer)” to promote awareness of the early detection and treatment
[PDF 136KB] -
May 11, 2016
Announcement of a Lawsuit Filed against Chugai
[PDF 91KB] -
May 11, 2016
Determination of Terms and Conditions of Stock Options
(Stock Acquisition Rights)
[PDF 113KB] -
Apr 25, 2016
Chugai and TWO CELLS Announce a License Agreement for "gMSC®1" a Regenerative Cellular Medicine for Chondrogenesis in the Knee
[PDF 110KB] -
Apr 22, 2016
Issuance of Stock Options (Stock Acquisition Rights)
[PDF 143KB] -
Apr 21, 2016
Launch of the Agent for Osteoporosis “Bonviva® Tablet 100 mg”
[PDF 93KB] -
Apr 20, 2016
Support for 2016 Kumamoto Earthquake
[PDF 67KB] -
Apr 19, 2016
F. Hoffmann-La Roche Announces First Quarter Sales 2016
[PDF 123KB] -
Mar 28, 2016
Chugai and Maruho Announce Marketing Approval of
"Marduox® Ointment" a Preparation for the Treatment of Psoriasis Vulgaris
(Combination Topical Ointment)
[PDF 79KB] -
Mar 25, 2016
Favorable Grand Panel Judgment on Patent-Infringement Lawsuit Regarding OXAROL® Ointment at the Intellectual Property High Court
[PDF 126KB] -
Mar 17, 2016
Chugai receives Orphan Drug Designation for Tocilizumab in Systemic Scleroderma
[PDF 148KB] -
Mar 17, 2016
Chugai Selected as a “Nadeshiko Brand” for the Second Consecutive Year
- Active Diversity Measures Continue to be Highly Appreciated by Outside Agencies - [PDF 91KB] -
Mar 07, 2016
Announcement on the Purchase of Land for Business
[PDF 107KB] -
Mar 06, 2016
Chugai Announces Phase II Global Study Results of Nemolizumab (CIM331) in Late-breaking Research Forums at AAD
[PDF 185KB] -
Mar 03, 2016
Chugai and BioMarin Enter Exclusive Sublicense Agreement
on the Patent of C-type Natriuretic Peptide Intended for Treatment of Achondroplasia
[PDF 80KB] -
Mar 02, 2016
Filing of Public Knowledge-Based Application for
Anti-Cancer Agent “Xeloda®” for Additional Indication of
Adjuvant Chemotherapy for Rectal Cancer
[PDF 108KB] -
Feb 22, 2016
Chugai Receives Excellence Award
from Tokyo Metropolitan Government Cancer Project
as a “Company Providing Support to Employees to
Keep a Good Balance between Cancer Treatment and Work”
[PDF 87KB] -
Feb 10, 2016
Chugai’s ALK Inhibitor “Alecensa®” Trial Stopped Early for Benefit
[PDF 155KB] -
Jan 28, 2016
Organizational and Personnel Changes
[PDF 191KB] -
Jan 28, 2016
Notice of Amendments to the Articles of Incorporation
[PDF 134KB] -
Jan 28, 2016
F. Hoffmann-La Roche Announces Financial Results for Fiscal 2015
[PDF 100KB] -
Jan 22, 2016
Agent for Osteoporosis Approved in Japan
“Bonviva® Tablet”
[PDF 108KB] -
Jan 22, 2016
Chugai Won the Grand Prize in the 18th NIKKEI Annual Report Awards
- Rated No.1 in Japan - [PDF 189KB] -
Jan 06, 2016
Chugai and Novartis Pharma to Terminate Co-Marketing Agreement of Aromatase Inhibitor “Femara® Tablets 2.5 mg,” a Treatment for Breast Cancer after Menopause
[PDF 152KB]
